Breztri
COPD
ApprovedCommercial
Key Facts
About AstraZeneca
AstraZeneca is one of the world's largest pharmaceutical companies, headquartered in Cambridge, UK, with a market capitalization of approximately $285 billion. The company focuses on transformative science including next-generation therapeutics, AI-driven drug discovery, and personalized medicine approaches. AstraZeneca reported strong commercial performance in 2025 with 16 positive Phase 3 study results announced during the year, demonstrating continued pipeline strength across multiple therapeutic areas.
View full company profileOther COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| Dupixent | Regeneron Pharmaceuticals | Phase 3 |
| Generic Spiriva (Tiotropium) | Lupin Limited | Approved |
| Brovana (arformoterol tartrate) | Bausch Health | Approved |
| GB-0895 | Generate Biomedicines | Phase 1 |
| Tiotropium/Olodaterol (Spiolto) | KYORIN Pharmaceutical | Approved |
| Yupelri® (revefenacin) | Cleo Life Sciences | Approved |